Showing posts with label chronic. Show all posts
Showing posts with label chronic. Show all posts

Analysis: Prognosis poor for U.N. chronic disease meeting

LONDON (Reuters) - Ten years after committing to fight AIDS, the United Nations is taking on an even bigger bunch of killers -- common chronic diseases -- in what is shaping up to be a bruising battle between big business, Western governments and the world's poor.

Tobacco, food and drinks companies are in the firing line for peddling products linked to cancer, diabetes and heart disease, while politicians in the rich world are accused of failing to set firm targets or provide funds for a decent fight.

"This is a once in a generation opportunity. We could save millions of lives here, and it's shameful and immoral that industry lobbying has put short-term profits in front of a public health disaster," Rebecca Perl of the World Lung Foundation (WLF) told Reuters. WLF has been involved in tetchy preliminary talks for several months.

The fear is that big business has successfully lobbied rich governments to be only half-hearted in battling non-communicable diseases, or NCDs, despite predictions that they could cripple healthcare systems of developing countries.

A bit like climate change, preventing and treating non-communicable diseases requires wealthy nations and multinational firms to take a near-term financial hit to help prevent poor nations being overwhelmed in the future.

In these austere times, fears are already growing that a high-level U.N. meeting in New York on September 19-20 -- only the second to focus on disease after one on AIDS in 2001 -- could be a flop.

The gathering will include scores of delegates from U.N. member states, including around 20 heads of government as well as representatives from public health groups, non-governmental organizations, the private sector and academia.

According to those close to the negotiations, a draft version of the political declaration that will form the cornerstone of the U.N.'s thinking on NCDs contains many platitudes but few tangible commitments.

"There are no strong, time-bound commitments in there," Ann Keeling, chair of the NCD Alliance which groups 2,000 health organizations from around the world, told Reuters. "It's a great disappointment from that point of view."

NOT ROCKET SCIENCE

The scale of the problem is immense. Around 36 million people die every year from NCDs -- around 80 percent of them in poor nations where prevention programs are virtually non-existent and access to diagnosis and treatment is very limited.

As a result, death rates from NCDs are nearly twice as high in poor countries as in the industrialized world.

Preventing these deaths -- or at least a good proportion of them -- isn't rocket science. Proven measures such as reducing smoking rates, improving diets, making simple drugs available and boosting exercise could knock a huge hole in that figure.

"There is a common story that unites cancer, cardiovascular, diabetes and respiratory medicines around tobacco, alcohol, diet and exercise -- and that is where we have the most cost-effective impact," says David Kerr, president of the European Society of Medical Oncology.

The crucial sticking points are targets, taxes and money.

Stopping a billion people from lighting up every day or providing cheap drugs like aspirin and statins to prevent heart attacks and strokes may be cost effective, but the payback won't be quick and it is unlikely to win many votes.

"The time horizon for the return on that investment is very long and beyond many political horizons. So it's difficult to get people to commit to these kinds of resources," says Gordon Tomaselli, president of the American Heart Association.

The NCD Alliance says spending $9 billion a year on tobacco control, food advice and treatment for people with heart risks would avert tens of millions of untimely deaths this decade.

Is that a lot? By comparison, caring for HIV patients in developing countries already costs around $13 billion a year.

In contrast to the AIDS fight that was the UN's focus a decade ago, the price of drugs is less an issue here, since many are available as cheap generics, although there are disputes over the cost of some more pricey products like insulin.

STUBBING OUT TOBACCO

The sharpest focus this time is on makers of fatty foods, sugary drinks and -- above all -- the tobacco industry, which World Health Organization director general Margaret Chan has described as "an industry that has much money and no qualms about using it in the most devious ways imaginable."

With tobacco predicted to kill more than a billion people this century, if current trends persist, the public health lobby says if the U.N. meeting does nothing else, it should at least make a smoke-free world one of its central targets.

Smoking alone causes one in three cases of lung disease, one in four cases of cancer, and one in 10 cases of heart disease, says Perl. "So look what a bang you get for your buck there."

Conflicted governments will find it tough. Japan Tobacco, for example, is 50 percent owned by the Japanese government, and the massive profits of U.S. cigarette makers bolster the U.S. economy.

In China, home to a third of the world's male smokers, the combination of taxes and sales from China National Tobacco -- a wholly state-owned entity -- account for around 9 percent of the government's annual fiscal revenues.

This is all the more reason, according to Paul Lincoln of the UK National Heart Forum and Jaakko Tuomilehto, an epidemiologist at the University of Helsinki, to hike cigarette taxes, curb advertising and insist on graphic health warnings.

"There are no more excuses," said Lincoln. "We have the know-how. The challenge as ever in public health is to overcome the ideological and vested interests."

Tuomilehto is more blunt: "It's a crazy thing to have a product in the shops that kills every second consumer -- it's madness."

(Editing by Sonya Hepinstall)


View the original article here

Scientists find gene that controls chronic pain

LONDON (Reuters) - British scientists have identified a gene responsible for regulating chronic pain, called HCN2, and say their discovery should help drug researchers in their search for more effective, targeted pain-killing medicines.

Scientists from Cambridge University said that if drugs could be designed to block the protein produced by the gene, they could treat a type of pain known as neuropathic pain, which is linked to nerve damage and often very difficult to control with currently available drugs.

"Individuals suffering from neuropathic pain often have little or no respite because of the lack of effective medications," said Peter McNaughton of Cambridge's pharmacology department, who led the study.

"Our research lays the groundwork for the development of new drugs to treat chronic pain by blocking HCN2."

Pain is an enormous health burden worldwide, estimated to cost more than 200 billion euros ($281 billion) a year in Europe and around $150 billion a year in the United States.

Studies show that around 22 percent of people with chronic pain become depressed and 25 percent go on to lose their jobs. A 2002/03 survey by a group called Pain in Europe estimated that as many as one in five Europeans suffers chronic pain.

Scientists have known about the HCN2 gene, which is found in pain-sensitive nerve endings, for several years, but had not yet fully understood its role in regulating pain.

Because a related gene called HCN4 plays a critical role in controlling electrical activity in the heart, McNaughton's team suspected that HCN2 might have a similar function and regulate electrical activity in pain-sensitive nerves.

For the study, published in the journal Science on Thursday, the researchers engineered the removal of the HCN2 gene from pain-sensitive nerves and then used electrical stimuli on these nerves in lab dishes to find out how the nerves had been changed by the removal of HCN2.

The scientists then studied genetically modified mice in which the HCN2 gene had been deleted. By measuring the speed the mice withdrew from different types of painful stimuli, the scientists were able to show that deleting the HCN2 gene took away neuropathic pain.

They also found that deleting HCN2 appeared to have no effect on normal acute pain -- such as the type of pain caused by accidentally cutting yourself or biting your own tongue -- a factor they said was important since this type of pain acts as a useful warning signal to the body.

"What is exciting about the work on the HCN2 gene is that removing it -- or blocking it pharmacologically -- eliminates neuropathic pain without affecting normal acute pain," McNaughton said in a statement about this work. "This finding could be very valuable clinically because normal pain sensation is essential for avoiding accidental damage."

Neuropathic pain, which is distinguished from inflammatory pain, is seen in patients with diabetes -- a condition which affects an estimated 280 million people around the world -- and as a painful after-effect of shingles and of chemotherapy in cancer patients. It is a also common factor in lower back pain and other chronic painful conditions.

(Reporting by Kate Kelland, Editing by Sitaraman Shankar)


View the original article here